Adripeg 50mg Injection is an anticancer medication that belongs to the class of anthracycline topoisomerase inhibitors that contains the active compound doxorubicin encapsulated in a closed lipid sphere (liposome) in which the liposomes are coated with polyethylene glycol (PEG). This coating with PEG enhances the circulation of the drug in the bloodstream that helps to deliver the drug from blood stream to cancerous cells rather than healthy ones. This medication is used as a monotherapy for patients with metastatic breast cancer, with an increased cardiac risk associated with conventional doxorubicin, ovarian cancer, AIDS-related Kaposi’s sarcoma and in combinational therapy of multiple myeloma (cancer of white blood cells called plasma cells). It is not recommended to use this drug if you are allergic to the active compound pegylated liposomal doxorubicin and its components. It is also not recommended for use if you are allergic to products like pea and soy. It is not recommended for use in childrens and adolescents aged below 18 years. It can be used in gediatric patients with dosage adjustments made based on age and body weight. The use of pegylated liposomal doxorubicin is not recommended if you are pregnant or nursing a child.  Use effective birth control during the treatment and for at least six months after the last dose. Pegylated liposomal doxorubicin may cause heart diseases. The drug should be administered carefully in patients with a history of cardiovascular disease, and cardiac function should be monitored regularly during the therapy. It is important to tell your doctor if you are receiving medicines for heart or liver disorders, have diabetes, Kaposi’s sarcoma or oral problems before taking Liposomal Doxorubicin Injection. Inform your physician about all the medications you take including herbal, over the counter medicines and supplements.